# GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

> **NCT00514163** · PHASE2 · COMPLETED · sponsor: **Japan Clinical Cancer Research Organization** · enrollment: 110 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine + S-1
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00514163
- **Lead sponsor:** Japan Clinical Cancer Research Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2011-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514163, "GEM vs GEM+TS-1 for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00514163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*